PROBLEM TO BE SOLVED: To provide a pharmaceutical preparation that is capable of highly efficiently inducing the skipping of the 44th exon of the human dystrophin gene, the pharmaceutical preparation being provided for the treatment of Duchenne muscular dystrophy.SOLUTION: According to the present invention, there is provided an antisense oligomer obtained by coupling between oligomers targeting two different sites of the 44th exon of the human dystrophin gene. Here, the antisense oligomer has a length of consecutive 15 to 30 bases and comprises coupling between a first unit oligomer containing a base sequence complementary to a first nucleotide sequence of consecutive 7 to 15 bases in a target exon and a second unit oligomer containing a base sequence complementary to a second nucleotide sequence of consecutive 7 to 15 bases in the target exon.SELECTED DRAWING: NoneCOPYRIGHT: (C)2018,JPO&INPIT【課題】デュシェンヌ型筋ジストロフィーの治療のための、ヒトジストロフィン遺伝子の第44番目のエクソンを高効率にスキッピングさせる薬剤の提供。【解決手段】ヒトジストロフィン遺伝子の第44番目のエクソンの異なる2か所を標的とするオリゴマーを連結して得られるアンチセンスオリゴマーであって、標的エクソン内の連続する7～15塩基の第1のヌクレオチド配列に相補的な塩基配列を含む第1のユニットオリゴマー、前記標的エクソン内の連続する7～15塩基の第2のヌクレオチド配列に相補的な塩基配列を含む第2のユニットオリゴマー、が連結した15～30塩基長のアンチセンスオリゴマー。【選択図】なし
